Boston Scientific

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell BSX and other ETFs, options, and stocks.

About BSX

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments.

CEO

Michael F. Mahoney

CEOMichael F. Mahoney

Employees

48,000

Employees48,000

Headquarters

Marlborough, Massachusetts

HeadquartersMarlborough, Massachusetts

Founded

1979

Founded1979

Employees

48,000

Employees48,000

BSX Key Statistics

Market cap

132.62B

Market cap132.62B

Price-Earnings ratio

75.68

Price-Earnings ratio75.68

Dividend yield

—

Dividend yield—

Average volume

5.77M

Average volume5.77M

High today

$91.93

High today$91.93

Low today

$89.02

Low today$89.02

Open price

$91.80

Open price$91.80

Volume

5.43M

Volume5.43M

52 Week high

$91.93

52 Week high$91.93

52 Week low

$53.93

52 Week low$53.93

BSX News

TipRanks 10h

Boston Scientific Launches 2025 Incentive Programs

Don't Miss our Black Friday Offers: Unlock your investing potential with TipRanks Premium - Now At 40% OFF! Make smarter investments with weekly expert stock p...

Simply Wall St 19h

Boston Scientific's three-year earnings growth trails the stellar shareholder returns

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company that is really flourishing, you can make...

Seeking Alpha 5d

Boston Sci stock climbs 5% on positive Watchman FLX data

Boston Scientific (NYSE:BSX) stock climbed 5% Monday after the medical device maker announced a study has shown its Watchman FLX device was superior to oral ant...

Analyst ratings

83%

of 35 ratings

Buy

82.9%

Hold

17.1%

Sell

More BSX News

Benzinga 5d

Why Is Medical Device Giant Boston Scientific Stock Trading Higher On Monday?

On Saturday, Boston Scientific Corporation BSX unveiled three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atria...